Keyword: Novartis

Kickbacks whistleblowers reached their "put up or shut up" moment for producing solid evidence—and didn't, Teva says.

Rebuilding Novartis’ rep is job one for CEO Vas Narasimhan after a series of kickback revelations culminated in a full-blown scandal in the U.S.

Shire could fill Takeda's gap of late-stage assets; GSK lays off 1,000 as a Bangladesh plant nears closure; Laekna gets two Novartis cancer drugs.

Pfizer breast-cancer fighter Ibrance posted a rare sales miss Tuesday, but it wasn't because Novartis and Lilly are stealing its share.

Amgen's top execs did little to appease fears about payer pushback on Aimovig during the company's earnings call.

Celgene is extracting volume-driven sales growth as the entire industry has come under scrutiny for its pricing.

Takeda's Alunbrig now sits in the back seat in ALK+ lung cancer, behind rivals from Pfizer, Novartis and Roche—but some new data could help change that.

PhRMA spent $15.5 million lobbying in the first half of the year, an 11.5% increase compared with the same period last year.

Novartis’ new Galaxies of Hope app was highlighted by Apple's App Store, helping to spur downloads of the game for the neuroendocrine tumor community.

In four suits filed before the Delaware District Court, Novartis is looking to block Gilenya generic entrance before 2027.